Teriparatide biosimilar - Richter-Helm Biotec

Drug Profile

Teriparatide biosimilar - Richter-Helm Biotec

Alternative Names: RGB-10

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Richter-Helm BioTec GmbH & Co. KG
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Osteoporosis

Most Recent Events

  • 04 Jan 2016 Preregistration for Osteoporosis in European Union (unspecified route)
  • 01 Jan 2014 Phase-III clinical trials in Osteoporosis in Germany (unspecified route) (Gedeon Richter annual report, June 2015)
  • 21 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top